KORU Medical Systems, Inc.
NASDAQ:KRMDMedical - Instruments & Supplies
+$0.06 today
- Market cap
- $149.64M
- Beta
- 0.42
- P/E (TTM)
- -80.2
- EPS (TTM)
- -$0.05
Volume 0.19M
Average 0.13M
KRMD Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
KORU Medical Systems, Inc.NASDAQ: KRMD
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $197.53K fell 9.1% year over year, behind the +4.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 10.2% from the prior quarter. Over 3 fiscal years it compounded at +11.3% a year.
Context
- Depreciation & amortization amounted to 2.0% of revenue in FY2025, down 0.3 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -9.1% toward the trailing-twelve-month pace of +4.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 810.5K USD
- Year-over-year change
- +4.9%
- 4-year CAGR
- +15.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 810.5K | +4.9% |
| FY2024 | 2024-12-31 | 772.89K | -11.2% |
| FY2023 | 2023-12-31 | 870.39K | +48.2% |
| FY2022 | 2022-12-31 | 587.14K | +26.8% |
| FY2021 | 2021-12-31 | 463.13K | — |
Depreciation & Amortization vs competitors
How KRMD compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +4.2% is the 5th highest of 10, against a peer median of +2.4%.
- Depreciation & amortization amounts to 1.8% of revenue for KRMD, versus a peer median of 7.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.23M USD | +2.4% | -0.2% | 9.3% | |
| LTM Mar 2026 | $9.54M USD | +11.9% | -10.7% | 8.4% | |
| LTM Mar 2026 | €5.27M EUR | +149.9% | +32.4% | 32.3% | |
| LTM Mar 2026 | $4.48M USD | -11.7% | +24.0% | 13.9% | |
| LTM Mar 2026 | $3.97M USD | +79.9% | -20.6% | 3.5% | |
| LTM Mar 2026 | $3.3M USD | +36.1% | +28.1% | 2.2% | |
| LTM Mar 2026 | $2.93M USD | +2.1% | -25.3% | 7.8% | |
| LTM Mar 2026 | $790.67K USD | +4.2% | +11.3% | 1.8% | |
| LTM Mar 2026 | $589K USD | -20.5% | +14.8% | 1.3% | |
| LTM Mar 2026 | $499.7K USD | -57.0% | -29.2% | 2.6% | |
| Peer median (excluding KRMD) | — | +2.4% | -0.2% | 7.8% | |
Competitors are the stored peer set for KRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 23.49M | 27.9M | 28.52M | 33.65M | 41.13M |
| Cost of Revenue | 9.72M | 12.53M | 11.81M | 12.31M | 15.52M |
| Gross Profit | 13.77M | 15.37M | 16.71M | 21.33M | 25.6M |
| Gross Margin | 58.6% | 55.1% | 58.6% | 63.4% | 62.3% |
| Research & Development | 2.47M | 4.96M | 5.74M | 5.26M | 4.39M |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 23.38M |
| Operating Expenses | 20.8M | 26.15M | 26.98M | 27.78M | 28.58M |
| Depreciation & Amortization | 463.13K | 587.14K | 870.39K | 772.89K | 810.5K |
| EBITDA | (5.9M) | (10.09M) | (8.9M) | (5.29M) | (1.81M) |
| EBITDA Margin | -25.1% | -36.2% | -31.2% | -15.7% | -4.4% |
| Operating Income | (7.03M) | (10.78M) | (10.27M) | (6.45M) | (2.97M) |
| Operating Margin | -29.9% | -38.6% | -36.0% | -19.2% | -7.2% |
| Interest Income | 13.08K | 145.59K | 561.33K | 444.64K | 293.4K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 665.09K | 105.71K | 496.4K | 382.49K | 356.41K |
| Income Before Tax | (6.36M) | (10.68M) | (9.77M) | (6.06M) | (2.62M) |
| Pre-Tax Margin | -27.1% | -38.3% | -34.3% | -18.0% | -6.4% |
| Income Tax Expense | (1.8M) | (2.01M) | 3.97M | 2.89K | 21.89K |
| Net Income | (4.56M) | (8.66M) | (13.74M) | (6.07M) | (2.64M) |
| Net Margin | -19.4% | -31.0% | -48.2% | -18.0% | -6.4% |
| EPS (Basic) | (0.10) | (0.19) | (0.30) | (0.13) | (0.06) |
| EPS (Diluted) | (0.10) | (0.19) | (0.30) | (0.13) | (0.06) |
| Weighted Avg Shares | 44.39M | 45M | 45.6M | 45.8M | 46.19M |
| Weighted Avg Shares (Diluted) | 44.39M | 45M | 45.6M | 45.8M | 46.19M |
KORU Medical Systems, Inc.
NASDAQ:KRMD
Intrinsic Alpha fair value
Locked
Current Price
$3.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.